Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.75 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.75 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.75 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.75 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.75 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958811 | 1.00 | CYP2C9 (0.75) | CYP2C9PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL958020 | 1.00 | CYP2C9 (0.75) | CYP2C9PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7916748 | 0.92 | CYP2C9 (0.74) | CYP2C9PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL719218 | 0.92 | CYP2C9 (0.74) | CYP2C9PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7916762 | 0.92 | CYP2C9 (0.74) | CYP2C9PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL10236572 | 0.89 | CYP2C9 (0.75) | CYP2C9PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL10236573 | 0.89 | CYP2C9 (0.75) | CYP2C9PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7920071 | 0.88 | CYP2C9 (0.73) | CYP2C9PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL10236500 | 0.88 | CYP2C9 (0.73) | CYP2C9PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL719888 | 0.88 | CYP2C9 (0.73) | CYP2C9PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946266-B2 | Substituted triazole and imidazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| EP-2454239-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | Janssen Pharmaceuticals Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011006903-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | CYP2C9 468/4885PSEN1 5/4885PSEN2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.